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multiple levels of parallelism offered by modern CPUs : 
Thread-level parallelism (TLP) is provided by expanding the 
particle transport physics to multiple CPU cores. On this 
level, the MC simulation is embarrassingly parallel so that 
each core runs its own simulation. However, gathering energy 
deposition events into one dose cube is challenging and needs 
to be orchestrated carefully using a buffered memory 
streaming technique. Data-level parallelism is achieved be 
re-engineering vital parts of the engine for Singe Instruction 
Multiple Data (SIMD) registers. Portability between a wide 
range of CPU generations is achieved by using APIs such as 
OpenMP, Cilk Plus and Intel MKL. PhiMC includes a source 
model for the dose delivery system and is capable of 
simulating clinical IMRT cases in the required spatial 
resolution of the dose grid. PhiMC has been implemented in 
C++ and the accuracy of the algorithms is validated against 
the original DPM framework using the Two One-Sided 
statistical Test (TOST) procedure. 
Results: We could show that the dose values calculated with 
PhiMC and DPM coincide at levels of 100% (for electrons) and 
99.7% (for photons) with a significance level of 0.05. 900 
million particle histories in water sampled from a 6 MV 
photon spectrum can be simulated in 47.3 seconds with a 
mean uncertainty of 0.32% on a dual Xeon workstation. An 
IMRT prostate plan with 9 beams and a voxel resolution of 
(1.95 x 1.95 x 2.0) mm³ could be simulated with 150 million 
histories in 16.2 seconds achieving a mean statistical 
uncertainty of 0.86%. A head&neck patient case using 9 
beams and a voxel resolution of (1.56 x 1.56 x 3.0) mm³ can 
be simulated in 8.2 seconds with an uncertainty of 0.89%. 
Conclusions: The dose of typical clinical IMRT plans can be 
simulated in less than 20 seconds with a mean uncertainty of 
less than 1% with our CPU-based PhiMC dose calculation 
framework. Compared to a GPU-based implementation of 
DPM (gDPM), PhiMC achieves better runtime results. In 
addition to that, a CPU implementation is not limited to a 
few GB of RAM and can therefore simulate larger plans or 
plans with a higher resolution.  
 
PO-0885   
Validation of a head and neck DVH prediction model for 
use in commercially available knowledge-based planning 
software 
L. Olsen1, J. Kavanaugh1, M. Yang1, H. Gay1, W. Thorstad1, S. 
Mutic1 
1Washington University School of Medicine, Radiation 
Oncology, Saint Louis, USA  
 
Purpose/Objective: A knowledge-based planning (KBP) 
algorithm was recently implemented into a commercial 
treatment planning system. The objective of this work was to 
evaluate the impact of training set plan quality on the ability 
of the KBP software to produce a high quality head and neck 
(HN) DVH prediction model and to validate the KBP model for 
clinical use. 
Materials and Methods: The KBP software was used to create 
an initial model for HN patients using a training set of 149 
plans from our clinical database. The training set included 
bilateral/unilateral, definitive and post-operative HN cases 
with arange of simultaneously integrated boost prescription 
dose levels determined from the clinical diagnosis. DVH 
prediction models were trained for the brain, brainstem, 
esophagus, larynx, lips, oral cavity, parotid glands, 
pharyngeal constrictors, spinal cord, and submandibular 
glands. Optic structures were excluded from the modeling 
process due to small structure volume and standard maximum 
dose objectives were used for optimization. The quality of 
each plan in the training cohort was assessed by comparing 
the clinically-approved DVHs to the DVHs predicted by the 
initial model. This method was used to identify dosimetric 
outliers where the clinical DVHs were sub-optimal to the 
predicted DVHs. Identified outliers (Table 1) were removed 
from the training set to create a refined model. A randomly 
selected 20 patient validation cohort was used to evaluate 
the impact of training set plan quality on the output of the 
DVH prediction model. This impact was assessed by 
comparing clinically relevant DVH metrics (mean dose or 
maximum dose) predicted by the refined model to those 
predicted by the initial model. The accuracy of the refined 
model to achieve predicted DVH values was evaluated by 
comparing DVH metrics predicted by the refined model to 
DVH metrics achieved in a replan using the refined HN model. 
Clinical acceptability was evaluated by comparing the DVH 
metrics in the clinically approved plan to the KBP model 
replan. 
Results: There was a a reduction in the average predicted 
mean/maximum dose in the refined model compared to the 
initial model (Table 1) for all structures included in the 
model. The refined HN model demonstrated excellent 
predictive accuracy, with a small average difference between 
clinical metrics of the KBP modal replan and the refined DVH 
predictions (Table 1). The ability of the HN model to produce 
clinically acceptable plans was demonstrated in the 20 
validation patients by similar clinical metrics achieved 
between the clinical plan and the KBP replan. 
 
 
 
 
Conclusions: This study validates that the developed KBP 
model systematically produces clinically acceptable plans for 
HN patients. The results demonstrate the impact of training 
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set plan quality on high-quality output of the KBP software. 
The validated HN model will be available for use in an 
upcoming clinical release of the KBP software. 
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Purpose/Objective: In this study we investigated the 
implementation of a new class-solution of volumetric 
modulated arc therapy (VMAT) for a three-phase adaptive 18F-
FDG-PET-voxel-based dose-painting-by-numbers (DPBN) dose-
escalation treatment. VMAT dose distributions were 
compared to the ones made using a standard 6-beam static 
intensity modulated radiotherapy (sIMRT) technique.  
Materials and Methods: 10 non-metastatic head-and neck 
cancer patients, enrolled in the adaptive arm of a phase II 
DPBN trial were planned both with sIMRT and VMAT. Separate 
treatment plans based on two pre and per-treatment (after 
the 8th fraction) 18F-FDG-PET/CTs and one per-treatment CT 
(after the 18th fraction) were made according to the trial 
protocol (Table 1). Dose distributions were summed on the 
pretreatment CT. Plans were evaluated in terms of dose 
levels, dose painting quality factors (QFs), treatment time 
and verified with Delta4 (Scandidos, Uppsala, Sweden) 
measurements.  
Table 1. Prescribed fraction dose for the three phase 
adaptive treatment protocol. The treatment plans for the 
first 2 phases were based on the 18F-FDG-PET/CT information, 
while for the third phase only CT data was used. 
Abbreviations: GTV = gross tumor volume; PTVHR = high-risk 
planning target volume (3 mm expansion of the high-risk 
clinical target volume - CTVHR); CTVHR = a three-dimensional 
GTV expansion of 1 cm adjusted to air cavities and 
uninvolved bones. 
 
 
 
Results: VMAT plans allowed the same level of dose 
escalation in the targets, while significantly reducing the 
dose to organs-at-risk (OARs). On average, the percentage of 
the ipsilateral parotid volume receiving at least 27 Gy was 
reduced from 44.0% to 38.8% and its median dose from 22.8 
to 19.5 Gy (p<0.05). Gross tumor volume QFs were 
significantly improved with VMAT. In 17 out of 20 phase I and 
phase II treatment plans, VMAT QF was better (maximum 
improvement 2.1%), while for the rest it was similar to sIMRT. 
Planning time of both techniques was similar and arc 
treatment delivery was 2 to 3 times faster. The Delta 4 
measurements were in very good agreement with the dose 
calculation for both types of plans. 
Conclusions: Biologically-guided volumetric modulated arc 
therapy is able to increase the sparing of OARs compared to 
sIMRT without compromising target doses or treatment 
delivery quality. Thus, it becomes a valuable technique for 
an adaptive treatment strategy, which follows the anatomical 
patient changes through the treatment time. The 
significantly faster VMAT delivery reduces the risk on intra-
fraction movement.  
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Purpose/Objective: Proton range uncertainties jeopardize 
the theoretical advantage of intensity modulated proton 
therapy over photon-based modalities. Depending on the 
heterogeneity level, this range uncertainty can grow up to 
4.6% of the nominal range + 1.2mm with typical analytical 
dose calculation methods (Paganetti 2012, PMB). The 
robustness of treatment plans can be further evaluated by 
simulating possible realizations of uncertainties with 
systematic and random components. Such a strategy may be 
a daunting task for analytical algorithms because 
computation time scales linearly with the number of 
scenarios simulated, which increases strongly if random 
errors are considered. Monte Carlo (MC) simulations offer 
here a double advantage: 1) they reduce the range 
uncertainty down to 2.4% + 1.2 mm; 2) they potentially allow 
simulating random errors with no significant increase in 
computation time. This study employs a fast MC tool, which 
can compute the impact of random errors in a single 
simulation. 
Materials and Methods: MCsquare, the new software created 
for this study, implements optimized algorithms on the Xeon 
Phi coprocessor to accelerate MC computations. MCsquare 
can compute a dose distribution in less than one minute. 
Multiple uncertainty scenarios are created. A 2.5 mm 
systematic setup error is modeled by shifting the CT image in 
all 6 directions of space. Random setup errors are modeled 
by a 1 mm random shift for each particle simulated by the MC 
engine. The uncertainty in the conversion from Hounsfield 
units to stopping powers is taken into account by applying a 
+/- 3% uniform bias to the patient densities. The experiment 
involves a water phantom, considering both a traditional plan 
with a PTV (2.5mm isotropic margin) and a robust plan (3% 
density uncertainty, 2.5 mm systematic setup errors). The 
CTV surrounds a circular organ-at-risk. The random error 
model employed in this study considers a large number of 
sampling, meaning an infinite number of fractions. The 
second experiment aims at determining the minimal number 
of fractions required to ensure the validity of this 
approximation. For this purpose, various sequences of 
fractions are generated, with different random errors. 
Results: The robustness of the treatment plan is easily 
verified by looking at the deviations of the DVH curve with 
respect to the nominal plan (red curve). The robust plan 
shows small deviations compared to the traditional PTV plan. 
Considering only random errors, the DVH distributions no 
longer vary for treatment with more than 30 fractions. This 
result validates the assumption of the infinite random 
sampling for our robustness test for typical fractionation 
strategies. 
